Calgary, Alberta – TheNewswire - August 29, 2024 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is pleased to announce the successful fabrication of an intraocular lens (IOL) that is designed to respond to muscle activity that controls the curvature of the natural lens in the human eye. This achievement puts Ocumetics one step closer to the first human implantation scheduled to occur in early 2025.
Accommodation is the ability to change the focus of the eye from distance to near. Accommodation is based on the ability of the natural lens of the eye to change its shape in response to forces exerted by the ciliary muscles, which surround the natural lens of the eye.
The Ocumetics accommodating IOL is designed to respond to these same natural forces by changing its shape in a way that changes its curvature and ultimately, its focus from near objects to objects in the distance. Using a precise measuring device called the IOLA, physiologic compression forces like the ones in the human eye were found to change the focal point of the Ocumetics lens from distance to a point a few inches away, which is similar to the ability of a 10-year-old person to accommodate.
“The results of this laboratory experiment validate the design of the Ocumetics accommodating IOL that has been theoretical, up until this point,” commented Dr. Garth Webb, Chief Scientist at Ocumetics, who has been working on design details of this lens for more than a decade.
“We believe this achievement will catapult Ocumetics to the forefront of accommodating lens design,” said Dean Burns, CEO of Ocumetics. “It is extremely satisfying to witness Dr. Webb’s aspiration become a reality.”
Demonstration of accommodation in response to forces believed to be generated in the human eye is an essential step toward finalization of lens design for the upcoming first-in-human lens implantations, scheduled for early next year.
For more information about Ocumetics Technology Corp. and our cutting-edge vision enhancement solutions, please visit Ocumetics.com.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.
Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dean Burns Dayton Marks
President and CEO Director
(817) 874-7564 (778) 347-2500
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
